PGD2R antagonist OC000459 vs placebo
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
- no estimate extracted1 study · 26 participantsVery low
Findings
What do systematic reviews say?
48 questions · 50 findings · 11 reviews
No studies found 7 · 14%GRADE not reported 3 · 6%Very low 24 · 48%Low 12 · 24%Moderate 4 · 8%High 0 · 0%
One‐food elimination diet vs six‐food elimination diet
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).
1 finding from 1 review
- RR 0.62 [0.11, 3.57]1 study · 129 participantsVery low
Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day)
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
1 finding from 1 review
- RR 3.09 [0.13, 73.17]4 studies · 233 participantsVery low
Vitamin D vs placebo/no treatment
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- RR 1.97 [0.18, 21.27]12 studies · 1251 participantsVery low
High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
- RR 0.89 [0.06, 13.08]3 studies · 104 participantsVery low
Infliximab 5 mg/kg vs purine analogues
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 0.7 [0.46, 1.06]2 studies · 355 participantsLow
Infliximab 5 mg/kg vs infliximab 10 mg/kg
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.03 [0.07, 15.79]1 study · 63 participantsVery low
Infliximab 5 mg/kg vs infliximab 20 mg/kg
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Infliximab 10 mg/kg vs infliximab 20 mg/kg
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.26 [0.7, 2.25]1 study · 220 participantsLow
Infliximab 5–10 mg/kg vs placebo
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 2.5 [0.12, 50.54]1 study · 94 participantsVery low
Antibiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Withdrawals due to adverse events · people with active UC
1 finding from 1 review
- Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 46 participantsGRADE not reported
Antibiotics vs probiotic
Withdrawals due to adverse events · people with active UC
1 finding from 1 review
- Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 50 participantsGRADE not reported
Antibiotics vs no treatment
Withdrawals due to adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
- Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 20 participantsGRADE not reported
Antibiotics vs placebo
Withdrawals due to adverse events · people with active UC
Antibiotics showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes onlyRR 2.06 [0.27, 15.72]8 studies · 691 participantsLow
Antibiotics plus probiotics vs placebo or no intervention
Withdrawals due to adverse events · people with active UC
It is very uncertain whether antibiotics plus probiotics changes withdrawals due to adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes onlyRR 1 [0.07, 15.08]2 studies · 98 participantsVery low
Belimumab 10 mg/kg vs placebo
Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.82 [0.63, 1.07]5 studies · 2890 participantsModerate
Opioids vs active comparators
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Withdrawals due to adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
1 finding from 1 review
- RR 0.38 [0.11, 1.3]3 studies · 531 participantsLow
TENS vs other active intervention
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
- Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low